Gilead Sciences to buy Arcellx, its cancer treatment partner, for $7.8 billion[1][2][3][4]. The acquisition will expand their collaboration on cell therapy development[1][3][4]. Gilead will pay $115 in cash for one share of Arcellx, representing a 79% gain over the stock's last closing price[2]. The companies have previously collaborated on the drug anito-cel[user]. GlobalData predicts $658 million in sales for this drug by 2032[user]. The acquisition will strengthen Gilead's position in the field of cell therapies against cancer[1][3].